Abstract
Introduction: Full-length osteopontin (OPN-FL), whose levels are elevated in association with atherosclerosis, is cleaved by thrombin, resulting in the formation of a putatively biologically-active N-terminal cleavage product (OPNN). This study addresses the hypothesis that statin and antiplatelet therapy in hypertensive patients specifically reduces OPN-N, rather than OPN-FL, in carotid plaques.
Methods: Seventy-four carotid plaques were collected from patients who underwent carotid endarterectomy (CEA). Plaque tissue was used to measure OPN proteins and for histological and immunohistochemical characterization.
Results: There were 22 statin-negative and 52 statin-treated patients. In the carotid plaque, immunohistochemical staining for macrophages was higher in statin-negative vs. statin-treated patients (high CD68 immunostaining was in 61.9 vs. 28.6%, p=.03, respectively). OPN-FL staining had a similar trend, but without statistical significance (78.7 vs. 47.8%, p=.08, respectively). Western blot analysis of plaque OPN-FL showed that statin treatment was not associated with significant alteration of its abundance, but with a significantly lower plaque content of OPN-N [median 0.08 (IQR 0.05-1.01) vs. 0.81 (IQR 0.27-2.86), respectively, p=.015]. Comparable pattern of association between OPN proteins and antiplatelet therapy was found: the abundance of OPN-FL was not different in plaques from untreated or treated patients, while the abundance of OPN-N was significantly reduced in antiplatelet treated vs. non-treated patients [0.08, (IQR 0.05-0.66) vs. 0.89, (IQR 0.13-1.94), p=0.004].
Conclusion: The effect of anti-atherosclerotic treatment on carotid plaques of hypertensive patients more readily associates with OPN-N than with OPN-FL expression, suggesting that anti-atherosclerotic treatment including statins and antiplatelet drugs modulates the "OPN system".
Keywords: Osteopontin, OPN-N terminal, carotid plaque, statin, antiplatelet.
Current Vascular Pharmacology
Title:Low Osteopontin N-Terminal Fragment and Carotid Plaque Stability Associated with Statin or Antiplatelet Therapy
Volume: 14 Issue: 3
Author(s): Rachel Hamias, Liobov Volvich, Esther Paran, Neta Sion-Vardi, Victor Novack, Gabriel Szendro, George Greenberg, Assaf Rudich and Talya Wolak
Affiliation:
Keywords: Osteopontin, OPN-N terminal, carotid plaque, statin, antiplatelet.
Abstract: Introduction: Full-length osteopontin (OPN-FL), whose levels are elevated in association with atherosclerosis, is cleaved by thrombin, resulting in the formation of a putatively biologically-active N-terminal cleavage product (OPNN). This study addresses the hypothesis that statin and antiplatelet therapy in hypertensive patients specifically reduces OPN-N, rather than OPN-FL, in carotid plaques.
Methods: Seventy-four carotid plaques were collected from patients who underwent carotid endarterectomy (CEA). Plaque tissue was used to measure OPN proteins and for histological and immunohistochemical characterization.
Results: There were 22 statin-negative and 52 statin-treated patients. In the carotid plaque, immunohistochemical staining for macrophages was higher in statin-negative vs. statin-treated patients (high CD68 immunostaining was in 61.9 vs. 28.6%, p=.03, respectively). OPN-FL staining had a similar trend, but without statistical significance (78.7 vs. 47.8%, p=.08, respectively). Western blot analysis of plaque OPN-FL showed that statin treatment was not associated with significant alteration of its abundance, but with a significantly lower plaque content of OPN-N [median 0.08 (IQR 0.05-1.01) vs. 0.81 (IQR 0.27-2.86), respectively, p=.015]. Comparable pattern of association between OPN proteins and antiplatelet therapy was found: the abundance of OPN-FL was not different in plaques from untreated or treated patients, while the abundance of OPN-N was significantly reduced in antiplatelet treated vs. non-treated patients [0.08, (IQR 0.05-0.66) vs. 0.89, (IQR 0.13-1.94), p=0.004].
Conclusion: The effect of anti-atherosclerotic treatment on carotid plaques of hypertensive patients more readily associates with OPN-N than with OPN-FL expression, suggesting that anti-atherosclerotic treatment including statins and antiplatelet drugs modulates the "OPN system".
Export Options
About this article
Cite this article as:
Hamias Rachel, Volvich Liobov, Paran Esther, Sion-Vardi Neta, Novack Victor, Szendro Gabriel, Greenberg George, Rudich Assaf and Wolak Talya, Low Osteopontin N-Terminal Fragment and Carotid Plaque Stability Associated with Statin or Antiplatelet Therapy, Current Vascular Pharmacology 2016; 14 (3) . https://dx.doi.org/10.2174/1570161113666150831142249
DOI https://dx.doi.org/10.2174/1570161113666150831142249 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phosphodiesterase 5 Inhibitors - Drug Design and Differentiation Based on Selectivity, Pharmacokinetic and Efficacy Profiles
Current Pharmaceutical Design Design of Second Generation Phosphodiesterase 5 Inhibitors
Current Topics in Medicinal Chemistry Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nutrient and Qualitative Phytochemical Analysis-evaluation of Antimicrobial Activity and Development of Products with Mulberry Leaves (<i>Mulberry indica</i> L.)
Current Nutrition & Food Science Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews The First Line of Defense Against Cardiac Hypertrophy
Current Molecular Medicine Profiling of Multiple Signal Pathway Activities by Multiplexing Antibody and GFP-Based Translocation Assays
Combinatorial Chemistry & High Throughput Screening Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets Food-derived Bioactive Peptides - Opportunities for Designing Future Foods
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor ?? (PPAR??) and Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Subject Index to Volume 2
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology The Plasma and Tissue Kininogen-kallikrein-kinin System: Role in the Cardiovascular System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Current Pharmaceutical Design Carnosine and Kidney Diseases: What We Currently Know?
Current Medicinal Chemistry Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Assessment and Management of Volume Overload Among Patients on Chronic Dialysis
Current Vascular Pharmacology The Effects of Lipid-Regulating Therapy on Haemostatic Parameters
Current Pharmaceutical Design Higher Waist Circumference, Fasting Hyperinsulinemia And Insulin Resistance Characterize Hypertensive Patients With Impaired Glucose Metabolism
Endocrine, Metabolic & Immune Disorders - Drug Targets